Core Viewpoint - The document outlines the procedures and responsibilities related to the resignation and departure of directors and senior management at Anhui Huaren Health Pharmaceutical Co., Ltd, ensuring compliance with relevant laws and maintaining corporate governance stability [1][3][4]. Group 1: Resignation Procedures - The company must complete the re-election of a director within 60 days if a resignation is submitted [1]. - Directors and senior management must provide a resignation report detailing the resignation date, reason, position, and any continued roles within the company [1]. - If a director's resignation results in the board falling below the legal minimum number of members, the original director must continue to perform their duties until a new director is appointed [3][4]. Group 2: Responsibilities and Obligations - Departing directors and senior management must hand over all relevant documents, seals, data assets, and unresolved matters within five working days after their resignation [5]. - They are required to cooperate with the company regarding any significant matters that occurred during their tenure and must not interfere with the company's operations post-departure [7]. - The loyalty obligations of departing directors and senior management remain in effect for three years after their resignation [7]. Group 3: Shareholding Restrictions - Departing directors and senior management are prohibited from transferring their shares within 12 months of the company's listing and are limited in the amount they can transfer during their tenure and for six months post-tenure [7].

General Principles - The company aims to strengthen management control over its subsidiaries and standardize internal operations to protect the rights of the company and its investors [1] - The company exercises shareholder rights through voting and appointing directors and supervisors to its subsidiaries, while also providing guidance and supervision [1][2] Management Principles - The management control over subsidiaries is intended to establish effective control mechanisms to enhance governance structure, asset management, and overall operational efficiency [1][2] - Subsidiaries must report significant business and financial matters that could impact the company [1][2] Establishment of Subsidiaries - The establishment of subsidiaries must comply with national laws and align with the company's strategic planning and core competitiveness [1][2] - Approval for establishing subsidiaries or mergers must follow the company's articles of association and investment management regulations [1][2] Governance Structure - The company collaborates with other shareholders to establish governance structures for subsidiaries, ensuring compliance with legal requirements [2] - The company appoints directors and supervisors to maintain governance oversight, with a majority of board members being company representatives [2][3] Financial Management - Subsidiaries must adhere to a unified accounting system and financial management practices dictated by the company [3] - Financial reports must be submitted timely, and the company has the right to audit and review subsidiary operations [3] Supervision and Accountability - The company supervises subsidiaries' operations, investments, and compliance with disclosure regulations [3] - Subsidiaries must maintain transparency and cannot engage in unauthorized financial activities [3] Miscellaneous Provisions - The provisions of this system will be executed in accordance with relevant laws and regulations, and the company board has the authority to interpret the system [4]

Meeting Overview - The company will hold its second extraordinary general meeting of shareholders on July 18, 2025, at 14:30, combining on-site and online voting methods [1][2] - The online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system from 9:15 to 15:00 on the same day [1][2] Voting Rights and Procedures - All shareholders registered by July 10, 2025, are entitled to attend the meeting and vote, either in person or by proxy [2][3] - Shareholders can only choose one voting method: on-site or online, with the first valid vote being counted in case of duplicate votes [2][3] Agenda Items - Proposals submitted for voting have been approved by the board and require at least two-thirds of the voting rights held by attending shareholders to pass [3] - The company will separately count and disclose the voting results of minority investors [3] Registration Details - Registration for the meeting can be done on-site, via mail, or email, with specific times and locations provided [4] - Natural persons must present identification and proof of shareholding, while legal entities must provide additional documentation [4] Online Voting Process - The company will provide a platform for online voting, with detailed procedures outlined for shareholders to follow [5][6] - Shareholders must complete identity verification to participate in online voting [5][6] Contact Information - The meeting will take place in Hefei, Anhui Province, with contact details provided for inquiries [5]

Core Viewpoint - The internal audit system of Anhui Huaren Health Pharmaceutical Co., Ltd. aims to ensure compliance, asset security, and the authenticity of financial reporting while enhancing operational efficiency and supporting the company's strategic development [2][4]. Group 1: Internal Control Objectives - Internal control is a process implemented by the board of directors, audit committee, management, and all employees to achieve control objectives [2]. - The goals of internal control include ensuring legal compliance in management, asset security, and the authenticity and completeness of financial reports [2]. Group 2: Internal Audit Structure - The company has established an internal audit department responsible for supervising business activities, risk management, internal controls, and financial information [4][6]. - The internal audit department reports to the board of directors and is supervised by the audit committee [4][6]. Group 3: Responsibilities of Internal Audit - The internal audit department is tasked with evaluating the effectiveness of internal controls, the authenticity of financial information, and the efficiency of business activities [4][5]. - Internal audit personnel must possess professional qualifications and adhere to ethical standards while conducting audits [4][10]. Group 4: Reporting and Evaluation - The internal audit department must report any significant deficiencies or risks in internal controls to the audit committee promptly [5][6]. - The audit committee is responsible for reviewing internal audit reports and providing written assessments of the effectiveness of internal controls to the board of directors [6][8]. Group 5: Compliance and Accountability - The company must disclose any significant deficiencies in internal controls to the Shenzhen Stock Exchange and outline the measures taken to address these issues [6][9]. - Internal audit personnel are protected by laws and regulations, and any obstruction or retaliation against them is prohibited [4][10].

Core Points - The document outlines the management system for the shares held by directors and senior management of Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the need for compliance with relevant laws and regulations [2][3][12] - It specifies the procedures for reporting share transactions by directors and senior management, including timelines for notification and disclosure [4][5][20] - The document establishes restrictions on the transfer of shares by directors and senior management, including limits on the number of shares that can be sold within a year and conditions under which shares cannot be transferred [6][8][19] Group 1 - The management system is established to enhance the oversight of shares held by directors and senior management, in accordance with the Company Law and Securities Law [2][3] - Directors and senior management must notify the board secretary in writing before buying or selling shares, and the board secretary is responsible for managing and verifying the information [4][12] - The document outlines the calculation of transferable shares, stating that newly acquired shares can only be transferred under specific conditions [3][5] Group 2 - Restrictions on share transfers include a maximum of 25% of total shares held per year and a six-month lock-up period after leaving the company [4][6][19] - Certain conditions prohibit directors and senior management from trading shares, such as during the period before financial report announcements and when under investigation for violations [8][18] - The document mandates that any changes in shareholding must be reported to the Shenzhen Stock Exchange within two trading days, including details of the transaction [20][9]

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is revising its Articles of Association to eliminate the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with relevant laws and regulations [1][2][3]. Summary by Sections Reason for Revision - The revision is based on the requirements of the Company Law of the People's Republic of China and related regulations, which state that the supervisory board will no longer be established, and its functions will be assumed by the audit committee of the board of directors [1][2]. Details of the Revision - The specific changes to the Articles of Association include the removal of the supervisory board and the corresponding rules, with updates to terminology such as changing "shareholders' meeting" to "shareholders' assembly" and updating numerical representations [1][2][3]. Other Matters - The board of directors has requested the shareholders' meeting to authorize the management to handle subsequent registration changes and filing of the revised Articles of Association [2][3].

Core Points - The implementation details of the cumulative voting system aim to enhance the corporate governance structure of Anhui Huaren Health Pharmaceutical Co., Ltd. and protect the interests of minority shareholders [3] - The cumulative voting system allows shareholders to allocate their voting rights across multiple candidates when electing two or more directors, providing flexibility in voting [3][5] - The election process for directors must comply with the company's articles of association and relevant laws, ensuring a structured and transparent nomination and voting process [3][4] Section Summaries General Provisions - The cumulative voting system is established to improve corporate governance and protect minority shareholders' interests, in accordance with relevant laws and regulations [3] - The system allows shareholders to have voting rights equal to the number of shares they hold multiplied by the number of directors to be elected [3] Election and Voting of Directors - The board must inform shareholders about the cumulative voting method before the election, and appropriate ballots must be prepared [2][3] - The election of independent and non-independent directors is conducted separately, with specific voting rights allocated for each category [5] - Shareholders can concentrate or distribute their votes among candidates, but exceeding the allowed number of votes will render the ballot invalid [5] Nomination of Director Candidates - Candidates for the board must be nominated by shareholders holding at least 1% of the company's shares or by the board itself [3] - Nominators must obtain consent from candidates and ensure they meet the qualifications for directorship [3][4] Election Results and Procedures - The number of elected directors must meet the requirements set forth in the company's articles of association, with a majority of votes needed for election [4] - If the number of elected directors is insufficient, additional rounds of voting will be conducted until the required number is met [4]

安徽华人健康医药股份有限公司 第一章 总则 第二章 信息披露暂缓与豁免的适用情形 第一条 为规范安徽华人健康医药股份有限公司（以下简称"公司"）信息披 露暂缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资 者的合法权益，根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司信息披露暂缓与豁免管理规定》《深圳证券交 易所创业板股票上市规则》（以下简称"《上市规则》"）等相关法 律法规，并结合《公司章程》及公司《信息披露管理制度》等有关规 定，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露按照中国证券监督管理委员会（以下简称"中国 证监会"）及深圳证券交易所（以下简称"深交所"）规定或者要求披 露的内容，适用本制度。 第三条 公司应当审慎确定信息披露暂缓、豁免事项，并采取有效措施防止暂 缓或者豁免披露的信息泄露。 第四条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披 露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者， 不得实施内幕交易、操纵市场等违法行为。 第十四条 公司和其他信息披露义务人应当在年度报告、半 ...

Core Viewpoint - The document outlines the procedures and requirements for selecting and changing accounting firms for Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the importance of maintaining independence and quality in the auditing process [1][2][3]. Group 1: General Principles - The audit fees for the accounting firm are determined by the shareholders' meeting [1] - The controlling shareholders and actual controllers are prohibited from designating accounting firms or interfering with the audit committee's independent duties [1] - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] Group 2: Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet the requirements set by the China Securities Regulatory Commission [1][2] - Firms must have a fixed workplace, sound organizational structure, and robust internal management systems [1] - The auditing team must include registered accountants who have not faced criminal or administrative penalties related to their professional conduct in the last three years [1][2] Group 3: Selection Procedures - The audit committee, independent directors, or a majority of the board can propose the hiring of an accounting firm [2][3] - The selection process must be competitive, utilizing methods such as competitive negotiation, public bidding, or invitation to tender [2][3] - The company must publicly disclose the selection documents, including evaluation criteria and scoring standards [2][3] Group 4: Evaluation and Reporting - The audit committee is responsible for evaluating the performance of the accounting firm annually and reporting to the board [2][3] - Evaluation criteria must include audit fees, qualifications, quality management, and risk management capabilities [4][5] - Significant changes in audit fees (over 20%) must be disclosed, including reasons for the change [6] Group 5: Change of Accounting Firms - The company must change accounting firms under specific circumstances, such as quality issues or failure to meet obligations [8][9] - The audit committee must communicate with both the outgoing and incoming firms to assess quality and integrity [9][10] - The reasons for changing firms must be disclosed, along with communication details with the previous firm [11][12]

安徽华人健康医药股份有限公司 防范控股股东及关联方资金占用管理制度 第一章 总则 第一条 为进一步完善安徽华人健康医药股份有限公司（以下简称"公司"）的法 人治理结构，加强资金管理， 应当严格防止公司 资金被占用。 其他方式向其提供资金； 防止和杜绝控股股东及关联方占用公司资金 行为的发生， 保护公司、股东和其他利益相关方的合法权益。根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司治理准则》、《深 圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》" ）、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》（以下简称"《规范运作指引》"）等法律、法规、规范 性文件和《安徽华人健康医药股份有限公司章程》（以下简称"公司章 程"）等规定，结合公司实际情况，特制定本制度。 经营性资金占用，是指公司控股股东及关联方通过采购、销售等生产经 营环节的关联交易所产生的资金占用；非经营性资金占用，是指公司为 控股股东及关联方垫付工资、福利、保险、广告等费用和其它支出，代 控股股东及关联方偿还债务而支付资金，有偿或无偿、直接 ...